Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media

IF 4.7 Q1 VIROLOGY Tumour Virus Research Pub Date : 2021-12-01 DOI:10.1016/j.tvr.2021.200224
Dan Jang , Sam Ratnam , Marek Smieja , David J. Speicher , Manuel Arias , Avery Clavio , Dustin Costescu , Laurie Elit , Shihai Huang , Erika Herrero-Garcia , Ajith M. Joseph , Hao Jiang , Robert Needle , Max Chernesky
{"title":"Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media","authors":"Dan Jang ,&nbsp;Sam Ratnam ,&nbsp;Marek Smieja ,&nbsp;David J. Speicher ,&nbsp;Manuel Arias ,&nbsp;Avery Clavio ,&nbsp;Dustin Costescu ,&nbsp;Laurie Elit ,&nbsp;Shihai Huang ,&nbsp;Erika Herrero-Garcia ,&nbsp;Ajith M. Joseph ,&nbsp;Hao Jiang ,&nbsp;Robert Needle ,&nbsp;Max Chernesky","doi":"10.1016/j.tvr.2021.200224","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To assess the concordance of high-risk HPV (HR-HPV) testing with the Alinity assay on cervical samples collected with diverse collection/storage protocols (ThinPrep, SurePath, Cervicollect) and to assess inter-assay concordance of HR-HPV testing of cervical cell specimens with Alinity m HR HPV assay (Alinity) vs cobas® 4800 HPV assay (cobas).</p></div><div><h3>Methods</h3><p>Specimens were obtained from 560 women attending a Women's Health clinic. Two specimens were obtained from each woman with combinations of two of the three collection devices and aliquots were tested by the two assays.</p></div><div><h3>Results</h3><p>Alinity showed an agreement of 93.9%, Kappa = 0.89 (263/280) between ThinPrep and SurePath specimens; 97.5%, Kappa = 0.95 (347/356) and 92.9%, Kappa = 0.85 (104/112) between ThinPrep and SurePath aliquots taken before or after cytology processing, respectively. Cervi-Collect specimens showed an agreement of 94.6%, Kappa = 0.89 (265/280) with ThinPrep specimens. Compared to cobas, Alinity showed agreements of 94.3%, Kappa = 0.88 (395/419) and 91.8%, Kappa = 0.82 (257/280) between ThinPrep and SurePath specimens, respectively. Alinity and cobas detected genotypes 16/18 and other high-risk HPV types at similar rates and showed similar correlations with cytology grades.</p></div><div><h3>Conclusions</h3><p>Compared to cobas, Alinity performed equally well for detecting HPV in cervical specimens obtained with ThinPrep and SurePath. The Cervi-Collect device compared well to the other collection methods. Alinity is a reliable assay for simultaneous detection of HPV-16/18 and other high-risk genotypes in cervical specimens.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200224","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumour Virus Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666679021000148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Objective

To assess the concordance of high-risk HPV (HR-HPV) testing with the Alinity assay on cervical samples collected with diverse collection/storage protocols (ThinPrep, SurePath, Cervicollect) and to assess inter-assay concordance of HR-HPV testing of cervical cell specimens with Alinity m HR HPV assay (Alinity) vs cobas® 4800 HPV assay (cobas).

Methods

Specimens were obtained from 560 women attending a Women's Health clinic. Two specimens were obtained from each woman with combinations of two of the three collection devices and aliquots were tested by the two assays.

Results

Alinity showed an agreement of 93.9%, Kappa = 0.89 (263/280) between ThinPrep and SurePath specimens; 97.5%, Kappa = 0.95 (347/356) and 92.9%, Kappa = 0.85 (104/112) between ThinPrep and SurePath aliquots taken before or after cytology processing, respectively. Cervi-Collect specimens showed an agreement of 94.6%, Kappa = 0.89 (265/280) with ThinPrep specimens. Compared to cobas, Alinity showed agreements of 94.3%, Kappa = 0.88 (395/419) and 91.8%, Kappa = 0.82 (257/280) between ThinPrep and SurePath specimens, respectively. Alinity and cobas detected genotypes 16/18 and other high-risk HPV types at similar rates and showed similar correlations with cytology grades.

Conclusions

Compared to cobas, Alinity performed equally well for detecting HPV in cervical specimens obtained with ThinPrep and SurePath. The Cervi-Collect device compared well to the other collection methods. Alinity is a reliable assay for simultaneous detection of HPV-16/18 and other high-risk genotypes in cervical specimens.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不同储存介质宫颈标本中Alinity m型HPV和cobas型HPV检测的比较
目的评估不同采集/储存方案(ThinPrep、SurePath、Cervicollect)宫颈标本中高危HPV (HR-HPV)检测与Alinity检测的一致性,并评估Alinity m HR HPV检测(Alinity)与cobas®4800 HPV检测(cobas)宫颈细胞标本中高危HPV检测的一致性。方法从一家妇女保健诊所的560名妇女中采集标本。从每名妇女身上获得两份标本,使用三种收集装置中的两种组合,并通过两种分析对等分进行测试。结果ThinPrep与SurePath样品的盐度一致性为93.9%,Kappa = 0.89 (263/280);在细胞学处理前和细胞学处理后,ThinPrep和SurePath分别为97.5%,Kappa = 0.95(347/356)和92.9%,Kappa = 0.85(104/112)。Cervi-Collect标本与ThinPrep标本的一致性为94.6%,Kappa = 0.89(265/280)。与cobas相比,Alinity的一致性为94.3%,Kappa = 0.88 (395/419); Alinity的一致性为91.8%,Kappa = 0.82(257/280)。Alinity和cobas检测到基因型16/18和其他高危型HPV的比例相似,并与细胞学分级显示相似的相关性。结论与cobas相比,Alinity在ThinPrep和SurePath获得的宫颈标本中检测HPV的效果相同。与其他收集方法相比,Cervi-Collect设备性能良好。Alinity是同时检测宫颈标本中HPV-16/18和其他高危基因型的可靠方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Tumour Virus Research
Tumour Virus Research Medicine-Infectious Diseases
CiteScore
6.50
自引率
2.30%
发文量
16
审稿时长
56 days
期刊最新文献
The imprint of viral oncoproteins on the variable clinical behavior among human papilloma virus-related oropharyngeal squamous cell carcinomas. Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: Association with malignant transformation in the lungs and clinical outcomes The SV40 virus enhancer functions as a somatic hypermutation-targeting element with potential tumorigenic activity Opportunities to advance cervical cancer prevention and care A new role for human papillomavirus 16 E2: Mitotic activation of the DNA damage response to promote viral genome segregation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1